Business context and reporting period
This is Ventrus BioSciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2012. The filing describes a development-stage specialty pharmaceutical company developing gastrointestinal treatments, with no product sales to date. Note: the request identifies Assembly Biosciences, Inc., but the filing itself names Ventrus BioSciences, Inc.; verify the issuer identity.
Financial results and position
| Metric | Q1 2012 | Q1 2011 / prior date |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $6.42 million | $0.97 million |
| General and administrative expense | $1.77 million | $1.70 million |
| Operating loss | $8.19 million | $2.67 million |
| Net loss | $8.17 million | $2.72 million |
| Basic and diluted loss per share | $0.66 | $0.38 |
| Net cash used in operations | $6.09 million | $1.81 million |
| Cash and cash equivalents | $31.07 million | $36.98 million at Dec. 31, 2011 |
| Current liabilities | $3.85 million | $2.51 million at Dec. 31, 2011 |
Total assets were $31.39 million and stockholders’ equity was $27.54 million at quarter-end. The balance sheet reported no debt; management said there were no outstanding loans during Q1. Cash declined by $5.91 million during the quarter. No gross margin is reported because the company had no product revenue.
Material changes and operating developments
- R&D expense rose 562% year over year, primarily from VEN 309 Phase III trial costs, related nonclinical and pharmacology work, and manufacturing for future studies. VEN 309 accounted for $5.82 million of Q1 R&D; VEN 307 accounted for $0.35 million.
- G&A increased about 4%, with higher salaries, taxes, board fees, rent and travel partly offset by lower stock-option expense.
- The company reported $16,181 of interest income and no interest expense in Q1 2012, versus $69,176 of interest expense in Q1 2011.
- Financing cash flow was $181,000, principally option exercise proceeds, net of shelf-registration costs. The $100 million shelf registration, including a possible $20 million at-the-market common-stock program, had not been used as of March 31, 2012.
Guidance, outlook, risks and unusual items
- Management estimated existing cash would fund operating needs and planned development activities through the third quarter of 2013. The company expects ongoing losses, rising R&D spending and no product revenue for at least several years; additional funding may be needed, and no external financing commitments were in place.
- VEN 309’s first U.S. pivotal Phase III data were expected in late June or early July 2012. A second pivotal trial and additional studies were conditional on the results, financing, regulatory considerations and intellectual-property position; a potential NDA filing was anticipated in 2014.
- VEN 307’s European Phase III results were expected in May 2012. Depending on those results and formulation work, the company planned either one U.S. Phase III trial using the existing formulation or two trials using a new formulation, with a potential NDA submission in 2013.
- The filing estimated remaining development costs of approximately $20 million for VEN 309 and $10 million for VEN 307 through specified trial milestones; broader completion estimates were $40 million for VEN 309, $20 million for VEN 307 and $15 million for VEN 308. Management cautioned that estimates could change materially.
- Funding may require equity, debt or collaborations on uncertain terms; equity could dilute shareholders, debt could add fixed obligations and covenants, and insufficient funding could delay or curtail programs or require surrendering product rights.
- Q1 net loss included no unusual noncash acquisition charge. The $12.5 million purchase price for VEN 309 (iferanserin), acquired in November 2011, had been expensed as R&D in 2011. Potential future obligations include licensing milestones and royalties; the filing also describes a $400,000 diltiazem development payment upon receipt of a final study report.
- Management concluded disclosure controls were effective and reported no material Q1 changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: the supplied metadata says Assembly Biosciences, while this filing is for Ventrus BioSciences.
- Review subsequent disclosures for VEN 309 and VEN 307 trial results, regulatory plans and changes to expected timelines or costs.
- Assess whether the stated cash runway remains achievable given trial spending, clinical accruals and other obligations.
- Check for financing activity, dilution, licensing payments or changes in the availability of additional capital after quarter-end.